Glofitamab as a SOC in third-line DLBCL and its potential in earlier lines of therapy

Glofitamab in R/R DLBCL: updated safety and efficacy dataПодробнее

The current and future role of bispecifics in R/R DLBCL: epcoritamab, glofitamab & moreПодробнее

ASH highlights: glofitamab in DLBCL & pirtobrutinib and epcoritamab in Richter's transformationПодробнее

Glofitamab, a CD20/CD3 bispecific antibody, in the treatment of R/R DLBCLПодробнее

Phase II study of glofitamab in patients with R/R LBCLПодробнее

The benefits of glofitamab in R/R DLBCL post-CAR-T therapyПодробнее

The use of ADCs & bispecific antibodies before and after CAR-T therapy in third-line DLBCLПодробнее

Glofitamab as a single agent in heavily pretreated patients with DLBCLПодробнее

Michael Dickinson, MBBS, DMedSc, on a Phase II Trial of Glofitamab in DLBCLПодробнее

Insights into Phase I/II study assessing fixed-duration glofitamab treatment for R/R LBCLПодробнее

Perspectives on Novel Antibody Platforms in DLBCLПодробнее

What is the rationale behind the combination of glofitamab + polatuzumab in patients with R/R DLBCL?Подробнее

Relapsed and Refractory Diffuse Large B-Cell LymphomaПодробнее

The emerging potential of bispecific antibodies as monotherapy & in combination for B-cell lymphomaПодробнее

Phase I study of costimulatory bispecific antibody RO7227166 combined with glofitamab in R/R B-NHLПодробнее

CD20/CD3 bispecific antibodies in R/R DLBCL: glofitamab and epcoritamabПодробнее

Updated results of glofitamab plus polatuzumab vedotin combination therapy in DLBCL, including HGBCLПодробнее

Glofitamab induces durable complete remissions in patients with relapsed large B-cell lymphomaПодробнее

Impact of TMTV on PFS following glofitamab treatment in R/R DLBCLПодробнее